The impact of BMI on outcomes of patients with metastatic renal cell carcinoma treated with targeted therapy: An external validation data set and analysis of underlying biology from The Cancer Genome Atlas.

被引：2

作者：

Albiges, Laurence

Hakimi, A. Ari

Lin, Xun

Simantov, Ronit

Zabor, Emily C.

Jacobsen, Anders

Furberg, Helena

Fay, Andre Poisl

Heng, Daniel Yick Chin

Signoretti, Sabina

McKay, Rana R.

Choueiri, Toni K.

机构：

[1] Dana Farber Canc Inst, Boston, MA 02115 USA

[2] Mem Sloan Kettering Canc Ctr, Dept Surg, Urol Serv, New York, NY 10021 USA

[3] Pfizer Oncol, La Jolla, CA USA

[4] Pfizer Oncol, New York, NY USA

[5] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

[6] Pontificia Univ Catolica Rio Grande do Sul, HSL, Oncol Serv, Porto Alegre, RS, Brazil

[7] Pontificia Univ Catolica Rio Grande do Sul, HSL, Oncol Res Unit, Porto Alegre, RS, Brazil

[8] Univ Calgary, Tom Baker Canc Ctr, Calgary, AB, Canada

[9] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA

[10] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA

来源：

关键词：

D O I：

10.1200/jco.2015.33.7_suppl.405

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

405

引用

页数：1